Hypogonadism induced by luteinising hormone releasing hormone agonist analogues: effects on bone density in premenopausal women

W H Matta; Matta WH; Shaw RW; R W Shaw; R. Hesp; Hesp R; D Katz; Katz D

doi:10.1136/bmj.294.6586.1523

Hypogonadism induced by luteinising hormone releasing hormone agonist analogues: effects on bone density in premenopausal women

W H Matta, Matta WH, Shaw RW, R W Shaw, R. Hesp, Hesp R, D Katz, Katz D

British medical journal (Clinical research ed.) · 1987 · vol. 294(6586) , pp. 1523–4 · doi:10.1136/bmj.294.6586.1523 · PMID:3111619 · PMC1246674

Other OA: closed

📄 Open PDF View on PubMed View at publisher

⚙ AI-generated summary by qwen3.7-flash, 2026-08-28 ⓘ

This paper investigates the effects of luteinising hormone releasing hormone agonist analogues on bone density in premenopausal women experiencing induced hypogonadism.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

MeSH descriptors

Bone and Bones Buserelin Hypogonadism Absorptiometry, Photon Adult Bone and Bones Buserelin Female Femur Femur Humans Hypogonadism Lumbar Vertebrae Lumbar Vertebrae Menopause Tomography, X-Ray Computed

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

Tamoxifen in the rat prevents estrogen-deficiency bone loss elicited with the LHRH agonist buserelin 1992

Cited by (1)

Tamoxifen in the rat prevents estrogen-deficiency bone loss elicited with the LHRH agonist buserelin 1992

Source provenance

europepmc: last seen: 2026-10-18T09:30:06.152893+00:00
pubmed: last seen: 2026-10-08T21:24:31.663940+00:00
unpaywall: last seen: 2026-10-19T06:34:38.229974+00:00